An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

BACKGROUND: Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patients with melanoma. However, prospective da...

Descripción completa

Detalles Bibliográficos
Autores principales: Sullivan, Ryan J., Atkins, Michael B., Kirkwood, John M., Agarwala, Sanjiv S., Clark, Joseph I., Ernstoff, Marc S., Fecher, Leslie, Gajewski, Thomas F., Gastman, Brian, Lawson, David H., Lutzky, Jose, McDermott, David F., Margolin, Kim A., Mehnert, Janice M., Pavlick, Anna C., Richards, Jon M., Rubin, Krista M., Sharfman, William, Silverstein, Steven, Slingluff, Craig L., Sondak, Vernon K., Tarhini, Ahmad A., Thompson, John A., Urba, Walter J., White, Richard L., Whitman, Eric D., Hodi, F. Stephen, Kaufman, Howard L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977556/
https://www.ncbi.nlm.nih.gov/pubmed/29848375
http://dx.doi.org/10.1186/s40425-018-0362-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977556/
https://www.ncbi.nlm.nih.gov/pubmed/29848375
http://dx.doi.org/10.1186/s40425-018-0362-6

Ejemplares similares